Table 2.

A brief overview of the potent therapeutic aptamers against coronavirus.

No	Name	Type	Target	Length	Sequence	IC50 (nM)	Viral target	SELEX	Ref
1–1	NG1	ssDNA	SARS-CoV Helicase	93	CCGTAATACGACTCACTATAGGGGAGCTCGGTACCGAATTCGTGTGAGGGTGAGATGTGTGTGTATTTGTCAAGCTTTGCAGAGAGGATCCTT	87.7	SARS-CoV	Ni-NTA magnetic beads	[23]
1–2	NG3				CCGTAATACGACTCACTATAGGGGAGCTCGGTACCGAATTCAGGTGGGCATGATTGTGTGTTTGTGTCGGTAAGCTTTCAGAGAGGATCCTT	120.8
1–3	NG8				CCGTAATACGACTCACTATAGGGGAGCTCGGTACCGAATTCATGTTGGTAGTTGGCTTGTGTTCGTGTGTTAAGCTTTGCAGAGAGGATCCTT	91.0
1–4	3′-inverted thymidine aptamer NG8				CCGTAATACGACTCACTATAGGGGAGCTCGGTACCGAATTCATGTTGGTAGTTGGCTTGTGTTCGTGTGTTAAGCTTTCAGAGAGGATCCTT	17.5
1–5	3′-biotin aptamer NG8				CCGTAATACGACTCACTATAGGGGAGCTCGGTACCGAATTCATGTTGGTAGTTGGCTTGTGTTCGTGTGTTAAGCTTTCAGAGAGGATCCTT	55.8
2–1	ES15-1	RNA	SARS-CoV NTPase/Helicase	107	GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGCAGAAAAGGGGGAAGAAGAGGGUGAUUCAGGCGAGAGAAUGGAUCCACAUCUACGAAUUC	RNA pool inhibitory effect: 1.2		Conventional SELEX	[24]
2–2	ES15-2				GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUCAGGGAGGAAAGGGGGAAGCGACUCAAGAACUGUAGAGGGAAUGGAUCCACAUCUACGAAUUC
2–3	ES15-3				GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUCCGGGCGGUCAAAGGAGAAGAAGAAAGAGAGAGCCCAGGGAAAUGGAUCCACAUCUACGAAUUC
2–4	ES15-4				GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGGAGGGAAAAGGGGAAGCGGAAAGGUUAAGGAUGCGGAGGAAUGGAUCCACAUCUACGAAUUC
2–5	ES15-5				GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGGUUAGGGGGAAAGGGGACCAGGUUCGCAGGAAAGCAGAGAAUGGAUCCACAUCUACGAAUUC
2–6	ES15-6				GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGGAAGGGAGAGCGGGAACAAGGAGAAAGAGAAGGGGAAUCCAAUGGAUCCACAUCUACGAAUUC